In pancreatic cancer, the PKD inhibitor CRT0066101 significantly suppressed NF-κB activity and the expression of NF-κB–dependent gene products essential for cell proliferation and survival [26]. This evidence concerns the gene NFKB1 and familial pancreatic carcinoma.